返回
Minerva Neurosciences Inc（NERV）价格
NERV 股价走势图
NERV 收益
Minerva Neurosciences Inc
$4.45
2.77%
$0.12
收盘价：Jan 16, 16:00:00 GMT-5
$4.34
-2.47%
$-0.11
盘前：Jan 20, 07:19:51 GMT-5
关键数据
前收盘价
$4.33
开盘价
$4.36
当日区间
$4.21 - $4.51
52周范围
$1.15 - $12.46
交易量
34.9K
平均成交量
2.1M
每股收益（TTM）
-1.85
股息收益率
--
市值
$30.3M
什么是 NERV？
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. The company is headquartered in Waltham, Massachusetts and currently employs 8 full-time employees. The company went IPO on 2014-06-25. The firm is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. The company has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.